First hour of intravenous infusion of chemotherapy or a highly complex drug or biologic that needs special handling and close monitoring, up to one hour.
- Medicare
- $133.27
- Work RVU
- 0.28
- Global, days
- Region
- General
Documentation requirements
What must appear in the operative or office note to support the claim.
Source · Editorial brief grounded in 3 cited references ↓
- Drug name, dose, and J-code with units
- Start and stop times showing more than 15 minutes
- Diagnosis supporting chemotherapy or complex biologic therapy
- Monitoring for infusion reactions
- Supervising physician present and trained staff administering
Applicable modifiers
Modifiers commonly billed with this code.
Source · AMA CPT modifier descriptors · CMS NCCI Policy Manual
What this code covers
Source · Editorial summary grounded in 3 cited references ↓
96413 is the initial hour of an IV infusion of chemotherapy or a complex biologic agent. The drug class drives this code, not the specialty. Agents that need specialized preparation and monitoring for serious reactions, such as some monoclonal antibodies, can qualify under payer policy.
Most orthopedic practices never bill it. It appears in orthopedic oncology programs treating bone and soft tissue sarcoma, and in multispecialty groups where rheumatology runs infusions of biologics alongside an ortho clinic. Staff giving these drugs need specific training, and the usual physician supervision rules for office infusions apply.
The frequent error in ortho is coding a bone health infusion like zoledronic acid for osteoporosis as chemotherapy. That is a therapeutic infusion (96365). Payers look closely at 96413 because it pays more than standard infusion codes. Document the drug, the reason it requires complex administration, start and stop times, and monitoring. Only one initial code per encounter. Facilities rank chemotherapy first under the hierarchy, and in the office the initial code goes to the main reason for the visit.
RVU & reimbursement
Component RVUs and Medicare national rate. Actual payment varies by GPCI locality.
Source · CMS Physician Fee Schedule, RVU26A · January 2026
Work RVU vs. total RVU
The work RVU (0.28) is the surgeon's own effort — the figure physician pay and productivity targets are built on. The total RVU (3.99) adds practice overhead and malpractice, and is what drives the Medicare payment below.
| Work RVU | 0.28 |
| Practice expense RVU | 3.64 |
| Malpractice RVU | 0.07 |
| Total RVU | 3.99 |
| Medicare national rate | $133.27 |
| Global period | days |
Payment by site of service
Medicare pays different rates by setting. HOPD typically pays substantially more than ASC for the same procedure.
Source · CMS OPPS Addendum B·ASC HCPCS payment rates·2026
| Setting | Medicare rate (national) |
|---|---|
Office (PFS non-facility) Procedure performed in physician's office | $133.27 |
HOPD (APC 5694) Hospital outpatient department | $337.46 |
Common denial reasons
The recurring reasons claims for CPT 96413 get rejected.
Source · Editorial brief grounded in CMS NCCI edits, AAOS coding appeals, and cited references ↓
- Drug does not qualify as chemotherapy or complex biologic under payer policy
- Osteoporosis infusions coded as chemotherapy
- Missing start and stop times
- Second initial code without separate IV site
- Prior authorization missing for the drug
Frequently asked questions
Source · Generated from the editorial pipeline, verified against 3 cited references ↓
01Can zoledronic acid be billed with 96413?
02Can an orthopedic practice bill 96413?
03Does 96413 require a minimum infusion time?
Sources & references
Editorial content was developed using the following public sources.
Mira Scribe
Mira Scribe documents the agent, timing, and monitoring in the note, so the chart shows why the infusion met the complex administration standard.
See how Mira captures CPT 96413 documentation